LP(A) AND CARDIOVASCULAR OUTCOMES: AN ANALYSIS FROM THE ODYSSEY OUTCOMES TRIAL

被引：15

作者：

Bittner, Vera ^{[1
]}

Szarek, Michael ^{[2
]}

Aylward, Philip E. ^{[3
]}

Bhatt, Deepak L. ^{[4
,5
]}

Diaz, Rafael ^{[6
]}

Fras, Zlatko ^{[7
]}

Goodman, Shaun ^{[8
]}

Hanotin, Corinne ^{[10
]}

Harrington, Robert ^{[9
]}

Jukema, J. W. ^{[11
]}

Loizeau, Virginie ^{[10
]}

Moriarty, Patrick ^{[12
]}

Moryusef, Angele ^{[13
]}

Pordy, Robert ^{[14
]}

Roe, Matthew T. ^{[15
]}

Sinnaeve, Peter ^{[16
]}

White, Harvey D. ^{[17
]}

Zahger, Doron ^{[18
]}

Zeiher, Andreas ^{[19
]}

Steg, Ph G. ^{[20
]}

Schwartz, Gregory ^{[21
]}

机构：

[1] Univ Alabama Birmingham, Birmingham, AL USA

[2] Suny Downstate Med Ctr, New York, NY USA

[3] Flinders Univ & Med Ctr, South Australian Hlth & Med Res Inst, Adelaide, SA 5001, Australia

[4] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA

[5] Harvard Med Sch, Boston, MA USA

[6] Estudios Cardiol Latinoamer, Rosario, Santa Fe, Argentina

[7] Univ Ljubljana, Ljubljana, Slovenia

[8] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[9] Stanford Univ, Stanford, CA 94305 USA

[10] Sanofi, Paris, France

[11] Leiden Univ, Med Ctr, Leiden, Netherlands

[12] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[13] Sanofi, Bridgewater, NJ USA

[14] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[15] Duke Univ, Duke Clin Res Inst, Durham, NC USA

[16] UZ Leuven, Leuven, Belgium

[17] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand

[18] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Beer Sheva, Israel

[19] Goethe Univ, Frankfurt, Germany

[20] Hop Bicetre, AP HP, Paris, France

[21] Univ Colorado, Aurora, CO USA

来源：

ATHEROSCLEROSIS SUPPLEMENTS | 2018年 / 32卷

关键词：

D O I：

10.1016/j.atherosclerosissup.2018.04.072

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

C3-5.01

引用

页码：24 / 25

页数：2

共 50 条

[31] Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial (vol 7, pg 618, 2019)
Ray, K. K.
Colhoun, H. M.
Szarek, M.
LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (08): : E20 - E20
[32] Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial (vol 7, pg 618, 2019)
Ray, K. K.
Colhoun, H. M.
Szarek, M.
LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (09): : E21 - E21
[33] Report of specific cardiovascular outcomes of the ADVANTAGE trial
Egilman, David S.
Presler, Amos H.
ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) : 781 - 781
[34] Insulin resistance and cardiovascular outcomes in the ORIGIN trial
Gerstein, Hertzel C.
Ferrannini, Ele
Riddle, Matthew C.
Yusuf, Salim
DIABETES OBESITY & METABOLISM, 2018, 20 (03): : 564 - 570
[35] Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Mahaffey, Kenneth W.
Hafley, Gail
Dickerson, Sheila
Burns, Shana
Tourt-Uhlig, Sandra
White, Jennifer
Newby, L. Kristin
Komajda, Michel
McMurray, John
Bigelow, Robert
Home, Philip D.
Lopes, Renato D.
AMERICAN HEART JOURNAL, 2013, 166 (02) : 240 - +
[36] Report of specific cardiovascular outcomes of the ADVANTAGE trial
Braunstein, N
Polis, A
ANNALS OF INTERNAL MEDICINE, 2005, 143 (02) : 158 - 159
[37] Canakinumab and cardiovascular outcomes: results of the CANTOS trial
Shah, Syed Raza
Abbasi, Zainab
Fatima, Mazia
Ochani, Rohan Kumar
Shahnawaz, Waqas
Khan, Muhammad Asim
Shah, Syed Arbab
JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2018, 8 (01): : 21 - 22
[38] Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
Tunon, Jose
Steg, Philippe Gabriel
Bhatt, Deepak L.
Bittner, Vera A.
Diaz, Rafael
Goodman, Shaun G.
Jukema, J. Wouter
Kim, Yong-Un
Li, Qian H.
Mueller, Christian
Parkhomenko, Alexander
Pordy, Robert
Sritara, Piyamitr
Szarek, Michael
White, Harvey D.
Zeiher, Andreas M.
Schwartz, Gregory G.
EUROPEAN HEART JOURNAL, 2020, 41 (42) : 4114 - 4123
[39] Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
Steg, Philippe Gabriel
Szarek, Michael
Bhatt, Deepak L.
Bittner, Vera A.
Bregeault, Marie-France
Dalby, Anthony J.
Diaz, Rafael
Edelberg, Jay M.
Goodman, Shaun G.
Hanotin, Corinne
Harrington, Robert A.
Jukema, J. Wouter
Lecorps, Guillaume
Mahaffey, Kenneth W.
Moryusef, Angele
Ostadal, Petr
Parkhomenko, Alexander
Pordy, Robert
Roe, Matthew T.
Tricoci, Pierluigi
Vogel, Robert
White, Harvey D.
Zeiher, Andreas M.
Schwartz, Gregory G.
CIRCULATION, 2019, 140 (02) : 103 - 112
[40] Colchicintherapie nach MyokardinfarktColchicine Cardiovascular Outcomes Trial (COLCOT)Colchicine treatment after myocardial infarctionColchicine Cardiovascular Outcomes Trial (COLCOT)
R. Klingenberg
S. Nitschmann
Der Internist, 2020, 61 : 766 - 769

← 1 2 3 4 5 →